Showing 4671-4680 of 5957 results for "".
- NIH-Funded Robotic Cane With 3D Camera Can Accurately Guide User to Chosen Locationhttps://modernod.com/news/nih-funded-robotic-cane-with-3d-camera-can-accurately-guide-user-to-chosen-location/2479504/Equipped with a color 3D camera, an inertial measurement sensor, and its own on-board computer, a newly improved robotic cane could offer blind and visually impaired users a new way to navigate indoors. When paired with a building’s architectural drawing, the device can accurately guide a user to
- Apellis Reports Mixed Phase 3 Results for Geographic Atrophy Drug; Will Pursue FDA Approvalhttps://modernod.com/news/apellis-announces-topline-results-from-phase-3-derby-and-oaks-studies-in-geographic-atrophy/2479503/Apellis Pharmaceuticals reported topline results from the phase 3 DERBY and OAKS studies evaluating intravitreal pegcetacoplan, an investigational targeted C3 therapy, in 1,258 adults with geographic atrophy (GA) secondary to age-related macular degeneration (AMD). B
- ProQR Announces Axiomer RNA Editing Licensing and Research Collaboration with Lillyhttps://modernod.com/news/proqr-announces-axiomer-rna-editing-licensing-and-research-collaboration-with-lilly/2479498/ProQR Therapeutics, the developer of RNA therapies for the treatment of genetic eye diseases, announced a global licensing and research collaboration with Eli Lilly and Company (Lilly) focused on the discovery, development, and commercialization of potential new medicines for genetic disorders in
- TearClear Files IND Application to Begin its Clinical Trial for TC-002 Latanoprost Ophthalmic Solutionhttps://modernod.com/news/tearclear-files-ind-application-to-begin-its-clinical-trial-for-tc-002-latanoprost-ophthalmic-solution/2479495/TearClear has filed an investigational new drug (IND) application to conduct a registrational study for its lead glaucoma candidate, TC-002 latanoprost ophthalmic solution 0.005%. Approximately 30%-40% of patients who rely on preserved, chronic glaucoma therapies show signs of moderat
- Pixium Vision Expands Collaboration with Stanford University On Next Generation Prima System Implantshttps://modernod.com/news/pixium-vision-expands-collaboration-with-stanford-university-on-next-generation-prima-system-implants/2479492/Pixium Vision SA announced the expansion of a collaboration with academic partner Stanford University to develop the second generation of implants for its bionic vision Prima System for dry age-related macular degeneration (AMD). “We are very excited to be extending our collaboration with
- Oxurion to Present Clinical and Preclinical Data at Upcoming Euretina 2021 Virtual Congresshttps://modernod.com/news/oxurion-to-present-clinical-and-preclinical-data-at-upcoming-euretina-2021-virtual-congress/2479493/Oxurion NV will be presenting preclinical and clinical data from its ongoing development programs, THR-149 and THR-687, as novel treatments for diabetic macular edema (DME) at the Euretina 2021 virtual congress. The upcoming annual meeting of the European Society of Retina Specialists is taking p
- EyeGate Pharma Completes Target Enrollment in Phase 2 Study to Evaluate PP-001 for the Treatment of Ocular Surface Inflammationhttps://modernod.com/news/eyegate-pharma-completes-target-enrollment-in-phase-2-study-to-evaluate-pp-001-for-the-treatment-of-ocular-surface-inflammation/2479490/EyeGate Pharmaceuticals announced that it has completed target enrollment of 21 patients in the phase 2 proof-of-concept (POC) study evaluating its lead product candidate, PP-001, in patients with ocular surface inflammation due to ocular surface diseases including dry eye. PP-001
- OD-OS Introduces Teleguidance Software for Navilas 577s Navigated Retina Laserhttps://modernod.com/news/od-os-introduces-teleguidance-software-for-navilas-577s-navigated-retina-laser/2479491/OD-OS has launched additional remote access capabilities for its Navilas Laser System 577s to address common challenges in ophthalmology that were enhanced during the COVID-19 pandemic. The new teleguidance capabilities give doctors remote access to the device to pre-plan a retinal laser treatmen
- Azura Ophthalmics Appoints Steven Altschuler, MD, as Chair of the Boardhttps://modernod.com/news/azura-ophthalmics-appoints-steven-altschuler-md-as-chair-of-the-board/2479486/Azura Ophthalmics announced the appointment of Steven M. Altschuler, MD, as chair of its board of directors. Dr. Altschuler brings more than 20 years of experience building, scaling, and leading health care and biotechnology companies. He currently serves as managing director of Healthcare Ventur
- Glaukos Submits Supplemental Pre-Market Approval Application for iStent Infinitehttps://modernod.com/news/glaukos-submits-supplemental-pre-market-approval-application-for-istent-infinite/2479482/Glaukos announced that it has submitted a supplemental pre-market approval (PMA) application to the FDA for the iStent infinite Trabecular Micro-Bypass System. The iStent infinite is an investigational device designed for use in a standalone procedure to reduce elevated IOP in p